DEF: BiomX Seeks Shareholder Approval for Acquisition, Reverse Split

BiomX Inc. is holding a special meeting on August 25, 2026, to vote on key proposals including the issuance of stock for an acquisition, a reverse stock split, and auditor ratification.

Summary

• BiomX Inc. is holding a Special Meeting of Stockholders on August 25, 2026, to vote on four proposals.
• Proposal 1 seeks approval for the issuance of BiomX common stock to Mandragola Ltd. in connection with the acquisition of controlling equity interests in Dr. Frucht Systems Ltd. (DFSL).
• Proposal 2 seeks approval for a reverse stock split of BiomX's common stock, with an aggregate ratio between 1-for-5 and 1-for-20, and a corresponding reduction in authorized shares from 750,000,000 to 150,000,000.
• Proposal 3 is to ratify the appointment of Barzily & Co. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Proposal 4 allows for the adjournment of the Special Meeting if necessary to solicit additional proxies for Proposals 1 and 2.
• The Board of Directors recommends a vote FOR all proposals.
• The record date for the meeting is August 10, 2026, with 26,559,607 shares outstanding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the necessity of a reverse stock split to maintain exchange listing and the ongoing substantial doubt about the acquired subsidiary's ability to continue as a going concern.

Positives

• The acquisition of Dr. Frucht Systems Ltd. (DFSL) is intended to expand BiomX's technology portfolio in LADAR-based detection systems for security and defense.
• The company is seeking to ratify Barzily & Co. as its independent auditor, ensuring continued financial oversight.
• The reverse stock split, if approved, aims to increase the stock price to meet NYSE American listing requirements and potentially attract investors and employees.
• The company is taking steps to address potential delisting by proposing a reverse stock split.

Negatives

• The acquired entity, Dr. Frucht Systems Ltd. (DFSL), has incurred losses and negative cash flows, with its auditors expressing substantial doubt about its ability to continue as a going concern.
• DFSL's financial statements for 2025 and 2024 show net losses of $119 thousand and $156 thousand, respectively.
• DFSL had a stockholders deficit of $859 thousand as of December 31, 2025.
• BiomX has already undergone two reverse stock splits in the past year (August 2024 and November 2025), indicating persistent stock price challenges.
• The proposed reverse stock split could lead to a reduction in liquidity and an increase in odd lot holders.
• The company's common stock price has recently been below $0.25 per share, raising concerns about potential delisting under proposed NYSE American rules.

Risks

• Failure to approve the Issuance Proposal could require renegotiation of acquisition terms with material adverse consequences.
• Failure to approve the Reverse Split Proposal could lead to continued non-compliance with NYSE American listing standards and potential delisting.
• The acquired company, DFSL, faces substantial doubt regarding its ability to continue as a going concern.
• The cumulative ratio of reverse stock splits could trigger delisting procedures if it exceeds 200-to-1 within a two-year period.
• Proposed NYSE American rule changes could lead to immediate delisting if the stock price remains below $0.25 per share.
• The issuance of new securities to Mandragola Ltd. will dilute existing stockholders' ownership and voting interests.
• The company is subject to the fragile and unpredictable security situation in Israel, where DFSL's operations are primarily located.

Future Outlook

The company is seeking stockholder approval for proposals that are critical for its continued listing on the NYSE American and for the integration of its recent acquisitions. The success of these proposals will significantly impact the company's future financial structure and operational capabilities. The acquired entity, DFSL, faces ongoing challenges related to its going concern status, which will require continued financial support and strategic management.

Management Comments

• The Board believes that granting discretion to the Board provides maximum flexibility to act in the best interests of the Company and its stockholders regarding the reverse stock split.
• The Board believes a higher stock price may help generate investor interest in the Company and help the Company attract and retain employees.
• If the Reverse Stock Split successfully increases the per share price of the Common Stock, the Board believes this increase may increase trading volume in the Common Stock and facilitate future financings by the Company.
• The Board has no present intention of using the additional available shares for anti-takeover purposes, and neither the Reverse Stock Split nor the reduction in authorized shares is being proposed in response to any effort of which we are aware to accumulate shares of our common stock or to obtain control of the Company.

Industry Context

StockSavvy.ai notes that BiomX operates in the defense and security technology sector, specifically focusing on LADAR-based detection systems. The proposed acquisition of DFSL aligns with industry trends towards advanced surveillance and counter-UAS technologies. However, the company's financial struggles, evidenced by the need for a reverse stock split and the precarious financial state of DFSL, highlight the capital-intensive nature and competitive pressures within this sector.

Comparison to Industry Standards

• The financial performance of Dr. Frucht Systems Ltd. (DFSL) is significantly below industry averages for established technology companies, with revenues in the low hundreds of thousands and substantial net losses.
• Companies in the defense and security technology sector often require significant R&D investment, but DFSL's current revenue generation and going concern issues suggest a gap in commercialization compared to peers.
• The need for multiple reverse stock splits by BiomX indicates a stock performance significantly lagging behind industry benchmarks for companies aiming for sustained growth and investor confidence on exchanges like NYSE American.
• Competitors in the counter-UAS and perimeter security markets, such as FLIR Systems (now Teledyne FLIR) or Raytheon Technologies, typically demonstrate much higher revenue streams and profitability, reflecting greater market penetration and scale.

Related Party Transactions

• BiomX acquired a 60% interest in Dr. Frucht Systems Ltd. (DFSL) from Mandragola Ltd.
• Mandragola Ltd. is entitled to a Revenue Bonus of 5% of DFSL's annual revenues of $25,000,000 or more, payable in stock or cash.
• Mandragola provided a line of credit of up to $2,000,000 to BiomX or its subsidiaries, evidenced by convertible promissory notes.
• BiomX issued a warrant to Mandragola to purchase up to 2,000,000 shares of common stock as consideration for the line of credit.
• BiomX acquired Zorro Net Ltd. from Water IO Ltd., issuing 1,300,000 shares of common stock and a $1,250,000 promissory note.
• DFSL has related party loans and accrued compensation payable to its stockholder and spouse, which were waived in April 2026.
• Water IO Ltd. received 800,000 restricted shares of common stock as consideration for an amendment and waiver to a promissory note.

Stakeholder Impact

• Existing shareholders will experience dilution from the issuance of new shares to Mandragola Ltd. and potentially from the conversion of notes and exercise of warrants.
• Shareholders may see a short-term increase in stock price if the reverse stock split is successful in meeting listing requirements, but long-term value depends on operational improvements.
• Employees may benefit from a potentially higher stock price, aiding in retention and attraction, but the company's overall financial health remains a concern.
• Creditors of DFSL may face increased risk due to the subsidiary's going concern issues and the need for continued financial support from BiomX.

Next Steps

• Stockholders will vote on the four proposals at the Special Meeting on August 25, 2026.
• If approved, the company will proceed with the issuance of securities to Mandragola Ltd. and the reverse stock split.
• The company will continue to support DFSL's operations, which are currently facing going concern issues.
• The company will file a registration statement for the resale of shares issued to Water IO Ltd. within 45 days of closing.

Key Dates

Recommendation

The company is at a critical juncture with significant upcoming votes on proposals that could impact its listing status and financial structure. While the acquisition of DFSL and ZorroNet offers potential strategic benefits, the financial health of DFSL and the persistent need for reverse stock splits indicate substantial underlying issues. A 'hold' recommendation reflects the uncertainty and the need to observe the outcomes of these proposals and the subsequent integration and operational performance before considering a more definitive investment stance.

Keywords

BiomX, Dr. Frucht Systems Ltd., Acquisition, Reverse Stock Split, Stockholder Meeting, NYSE American, Mandragola Ltd., Auditor Ratification